Skip to main content

Table 2 Change in study parameters during the follow-up period

From: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Cohort Dulaglutide, n = 30 Liraglutide, n = 30
Parameter Baseline Mean ± SEM Follow-up Mean ± SEM Change Mean ± SEM P Baseline Mean ± SEM Follow-up Mean ± SEM Change Mean ± SEM P
Body weight (kg) 87.17 ± 2.16 82.97 ± 2.05 −4.20 ± 0.47 < 0.001 89.43 ± 2.60 83.60 ± 2.35 −5.83 ± 0.87 < 0.001
BMI (kg/m2) 32.84 ± 0.77 31.312 ± 0 .68 −1.53 ± 0.21 < 0.001 34.92 ± 0.868 32.650 ± 0.77 −2.27 ± 0.33 < 0.001
SBP (mmHg) 134.30 ± 2.71 130.87 ± 2.49 −3.43 ± 2.97 0.258 137.83 ± 2.503 127.60 ± 2.07 −10.23 ± 2.36 < 0.001
DBP (mmHg) 80.73 ± 1.64 78.43 ± 0.914 − 2.30 ± 1.79 0.208 83.47 ± 1.587 80.67 ± 1.51 − 2.80 ± 1.85 0.141
FPG(mg/dl) 175.53 ± 11.45 133.67 ± 6.90 − 41.87 ± 12.72 0.003 160.13 ± 8.17 115.93 ± 5.69 − 44.20 ± 8.05 < 0.001
HbA1c (%) 8.43 ± 0.21 7.411 ± 0.15 −1.017 ± 0.22 < 0.001 8.49 ± 0.26 6.95 ± 0.21 − 1.547 ± 0.22 < 0.001